Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

Author's Avatar
May 08, 2023

Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering. The gross proceeds of the offering are expected to be approximately $350 million, before offering expenses, which together with the Company’s existing cash and cash equivalents, will enable the Company to fund its planned operating expenses and capital expenditures through the fourth quarter of 2025. All ADSs to be sold in the offering will be sold by Legend Biotech. The offering is expected to close on or about May 10, 2023, subject to customary closing conditions.